欧洲健康足月婴儿呼吸道合胞病毒疾病负担:一项前瞻性出生队列研究
该多中心前瞻性观察性出生队列研究在五个欧洲国家站点纳入9154名健康足月婴儿(胎龄≥37周),随访第一年,通过父母问卷和病历回顾确定RSV相关住院发生率,并在993名婴儿的嵌套队列中主动监测RSV感染。结果:总队列RSV相关住院发生率为1.8%(95%CI 1.6-2.1),145例RSV相关住院中8例入住儿科重症监护室(占5.5%,占总队列0.09%);主动监测队列中任何诊断方法确诊的RSV感染发生率为26.2%(95%CI 24.0-28.6),就医RSV感染发生率为14.1%(95%CI 12.3-16.0)。作者认为,对孕妇或健康足月婴儿在第一个冬季进行免疫接种可能对RSV感染造成的医疗负担产生重大影响。
要点
- 健康足月婴儿第一年RSV相关住院发生率为1.8%(95%CI 1.6-2.1),即每56名健康足月婴儿中有1名因RSV相关急性呼吸道感染住院。
- 145例RSV相关住院中8例入住儿科重症监护室,占RSV相关住院的5.5%,占总队列的0.09%。
- 嵌套主动监测队列(993名婴儿)中,任何诊断方法确诊的RSV感染发生率为26.2%(95%CI 24.0-28.6)。
- 嵌套主动监测队列中就医RSV感染发生率为14.1%(95%CI 12.3-16.0)。
- 作者认为,对孕妇或健康足月婴儿在第一个冬季进行免疫接种可能对RSV感染造成的医疗负担产生重大影响。
适用人群与场景
- 健康足月出生婴儿(胎龄≥37周),来自五个欧洲国家站点,2017年7月1日至2020年4月1日出生,随访第一年。
- 总队列9154名婴儿;嵌套主动监测队列993名婴儿。
研究设计与关键结果
- 研究类型:多中心、前瞻性、观察性出生队列研究,在五个欧洲国家站点开展;注册号ClinicalTrials.gov NCT03627572。
- 总队列9154名健康足月婴儿随访第一年,RSV相关住院发生率为1.8%(95%CI 1.6-2.1)。
- 145例RSV相关住院中8例入住儿科重症监护室,占RSV相关住院的5.5%,占总队列的0.09%。
- 嵌套主动监测队列993名婴儿中,任何诊断方法确诊的RSV感染发生率为26.2%(95%CI 24.0-28.6)。
- 嵌套主动监测队列中就医RSV感染发生率为14.1%(95%CI 12.3-16.0)。
- 作者结论:RSV相关急性呼吸道感染导致 substantial 疾病负担,在高收入环境中每56名健康足月婴儿中有1名因此住院。
证据类型、等级与局限
- 证据类型:多中心前瞻性观察性出生队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对孕妇或健康足月婴儿在第一个冬季进行免疫接种可能对RSV感染造成的医疗负担产生重大影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.
METHODS: We performed a multicentre, prospective, observational birth cohort study in healthy term-born infants (≥37 weeks of gestation) in five sites located in different European countries to determine the health-care burden of RSV. The incidence of RSV-associated hospitalisations in the first year of life was determined by parental questionnaires and hospital chart reviews. We performed active RSV surveillance in a nested cohort to determine the incidence of medically attended RSV infections. The study is registered with ClinicalTrials.gov, NCT03627572.
FINDINGS: In total, 9154 infants born between July 1, 2017, and April 1, 2020, were followed up during the first year of life and 993 participated in the nested active surveillance cohort. The incidence of RSV-associated hospitalisations in the total cohort was 1·8% (95% CI 1·6-2·1). There were eight paediatric intensive care unit admissions, corresponding to 5·5% of 145 RSV-associated hospitalisations and 0·09% of the total cohort. Incidence of RSV infection in the active surveillance cohort confirmed by any diagnostic assay was 26·2% (24·0-28·6) and that of medically attended RSV infection was 14·1% (12·3-16·0).
INTERPRETATION: RSV-associated acute respiratory infection causes substantial morbidity, leading to the hospitalisation of one in every 56 healthy term-born infants in high-income settings. Immunisation of pregnant women or healthy term-born infants during their first winter season could have a major effect on the health-care burden caused by RSV infections.
FUNDING: Innovative Medicines Initiative 2 Joint Undertaking, with support from the EU's Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations.
参考来源
- Wildenbeest JG, Billard MN, Zuurbier RP, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2022. PMID: 36372082. doi:10.1016/S2213-2600(22)00414-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。